Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia

References

• Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA: a Cancer Journal for Clinicians. 2017 Jan;67(1):7–30.
   PubMed Web of Science ®Google Scholar
• Burnett AK, Russell NH, Hills RK, et al. A randomized comparison of daunorubicin 90 mg/m2 vs. 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood. 2015 Jun 18;125(25):3878–3885.
   PubMed Web of Science ®Google Scholar
• Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. The New England Journal of Medicine. 2009 Sep 24;361(13):1249–1259.
   PubMed Web of Science ®Google Scholar
• Lee JH, Joo YD, Kim H, et al. A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia. Blood. 2011 Oct 6;118(14):3832–3841.
   PubMed Web of Science ®Google Scholar
• Lowenberg B, Ossenkoppele GJ, Van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. The New England Journal of Medicine. 2009 Sep 24;361(13):1235–1248.
   PubMed Web of Science ®Google Scholar
• Luskin MR, Lee JW, Fernandez HF, et al. Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups. Blood. 2016 Mar 24;127(12):1551–1558.
   PubMed Web of Science ®Google Scholar
• Preisler H, Davis RB, Kirshner J, et al. Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: a cancer and leukemia group B study. Blood. 1987 May;69(5):1441–1449.
   PubMed Web of Science ®Google Scholar
• Berman E, Heller G, Santorsa J, et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood. 1991 Apr 15;77(8):1666–1674.
   PubMed Web of Science ®Google Scholar
• Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017 Jan 26;129(4):424–447.
   PubMed Web of Science ®Google Scholar
• Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2016. CA: a Cancer Journal for Clinicians. 2016 Jul;66(4):271–289.
   PubMed Web of Science ®Google Scholar
• Damle NK, Frost P. Antibody-targeted chemotherapy with immunoconjugates of calicheamicin. Current Opinion in Pharmacology. 2003 Aug;3(4):386–390.
   PubMed Web of Science ®Google Scholar
• Ricart AD. Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research. 2011 Oct 15;17(20):6417–6427.
   PubMed Web of Science ®Google Scholar
• Linenberger ML. CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance. Leukemia. 2004 12/09/online;19(2): 176–182.
   Web of Science ®Google Scholar
• van der Velden VH, te Marvelde JG, Hoogeveen PG, et al. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood. 2001 May 15;97(10):3197–3204.
   PubMed Web of Science ®Google Scholar
• Mylotarg (gemtuzumab ozogamicin) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals; September 2017.
   Google Scholar
• FDA Oncologic Drugs Advisory Committee Briefing Document (BLA 761060) - Gemtuzumab Ozogamicin. 2017 July 11, [cited 2018 Mar 3]; Available from: https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM566015.pd
   Google Scholar
• Larson RA, Sievers EL, Stadtmauer EA, et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer. 2005 Oct 1;104(7):1442–1452.
   PubMed Web of Science ®Google Scholar
• Bross PF, Beitz J, Chen G, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research. 2001 Jun;7(6):1490–1496.
   PubMed Web of Science ®Google Scholar
• Arceci RJ, Sande J, Lange B, et al. Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia. Blood. 2005 Aug 15;106(4):1183–1188.
   PubMed Web of Science ®Google Scholar
• Petersdorf SH, Kopecky KJ, Slovak M, et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood. 2013 Jun 13;121(24):4854–4860.
   PubMed Web of Science ®Google Scholar
• Richwine L Pfizer pulls Leukemia Drug from U.S. Market. 2010 [cited 2017 Oct 15]; Available from: https://www.reuters.com/article/us-pfizer-mylotarg/pfizer-pulls-leukemia-drug-from-u-s-market-idUSTRE65K5QG20100621
   Google Scholar
• Taksin AL, Legrand O, Raffoux E, et al. High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group. Leukemia. 2007 Jan;21(1):66–71.
   PubMed Web of Science ®Google Scholar
• Castaigne S, Pautas C, Terre C, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet (London, England). 2012 Apr 21;379(9825):1508–1516.
   PubMed Web of Science ®Google Scholar
• Jen EY, Ko C-W, Lee JE, et al. FDA approval: gemtuzumab ozogamicin for the treatment of adults with newly-diagnosed CD33-positive acute myeloid leukemia. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research. 2018 Feb 23:clincanres.3179.2017.
   Google Scholar
• Lambert J, Lambert J, Nibourel O, et al. MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin. Oncotarget. 2014 Aug 15;5(15):6280–6288.
   PubMedGoogle Scholar
• Renneville A, Abdelali RB, Chevret S, et al. Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: results of the ALFA-0701 trial. Oncotarget. 2014 Feb 28;5(4):916–932.
   PubMedGoogle Scholar
• Hills RK, Castaigne S, Appelbaum FR, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. The Lancet Oncology. 2014 Aug;15(9):986–996.
   PubMed Web of Science ®Google Scholar
• Burnett AK, Hills RK, Milligan D, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2011 Feb 1;29(4):369–377.
   PubMed Web of Science ®Google Scholar
• Delaunay J, Recher C, Pigneux A, et al. Addition of gemtuzumab ozogamycin to chemotherapy improves event-free survival but not overall survival of AML patients with intermediate cytogenetics not eligible for allogeneic transplantation. Results of the GOELAMS AML 2006 IR study. Blood. 2011;118(Abstract 79).
   Google Scholar
• Burnett AK, Russell NH, Hills RK, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2012 Nov 10;30(32):3924–3931.
   PubMed Web of Science ®Google Scholar
• Amadori S, Suciu S, Selleslag D, et al. Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: results of the randomized phase III EORTC-GIMEMA AML-19 trial. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2016 Mar 20;34(9):972–979.
   PubMed Web of Science ®Google Scholar
• Lamba JK, Chauhan L, Shin M, et al. CD33 splicing polymorphism determines gemtuzumab ozogamicin response in de novo acute myeloid leukemia: report from randomized phase III children’s oncology group trial AAML0531. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2017 Aug 10;35(23):2674–2682.
   PubMed Web of Science ®Google Scholar
• Gale RE, Popa T, Wright M, et al. No evidence that CD33 splicing SNP impacts the response to GO in younger adults with AML treated on UK MRC/NCRI trials. Blood. 2018 Jan 25;131(4):468–471.
   PubMed Web of Science ®Google Scholar
• Pollard JA, Loken M, Gerbing RB, et al. CD33 expression and its association with gemtuzumab ozogamicin response: results from the randomized phase III children’s oncology group trial AAML0531. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2016 Mar 1;34(7):747–755.
   PubMed Web of Science ®Google Scholar
• Olombel G, Guerin E, Guy J, et al. The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia. Blood. 2016 Apr 28;127(17):2157–2160.
   PubMed Web of Science ®Google Scholar
• Goemans BF, Zwaan CM, Vijverberg SJ, et al. Large interindividual differences in cellular sensitivity to calicheamicin may influence gemtuzumab ozogamicin response in acute myeloid leukemia. Leukemia. 2008 Dec;22(12):2284–2285.
   PubMed Web of Science ®Google Scholar
• Bertoli S, Berard E, Huguet F, et al. Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia. Blood. 2013 Apr 4;121(14):2618–2626.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2010 Feb 1;28(4):562–569.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2012 Jul 20;30(21):2670–2677.
   PubMed Web of Science ®Google Scholar
• Blum W, Garzon R, Klisovic RB, et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proceedings of the National Academy of Sciences of the United States of America. 2010 Apr 20;107(16):7473–7478.
   PubMed Web of Science ®Google Scholar
• Welch JS, Petti AA, Miller CA, et al. TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes. The New England Journal of Medicine. 2016 Nov 24;375(21):2023–2036.
   PubMed Web of Science ®Google Scholar
• Daver N, Kantarjian H, Ravandi F, et al. A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome. Leukemia. 2016 Feb;30(2):268–273.
   PubMed Web of Science ®Google Scholar
• Nand S, Othus M, Godwin JE, et al. A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia. Blood. 2013 Nov 14;122(20):3432–3439.
   PubMed Web of Science ®Google Scholar
• Candoni A, Papayannidis C, Martinelli G, et al. Flai (fludarabine, cytarabine, idarubicin) plus low-dose gemtuzumab ozogamicin as induction therapy in CD33-positive AML: final results and long term outcome of a phase II multicenter clinical trial. Am J Hematol. 2018 May;93(5):655–663.
   PubMed Web of Science ®Google Scholar
• Wang ES, Zeidan A, Tan W, et al. Cytoreduction with gemtuzumab ozogamicin and cytarabine prior to allogeneic stem cell transplant for relapsed/refractory acute myeloid leukemia. Leukemia & Lymphoma. 2012 Oct;53(10):2085–2088.
   PubMed Web of Science ®Google Scholar
• Wattad M, Weber D, Dohner K, et al. Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure. Leukemia. 2017 Jun;31(6):1306–1313.
   PubMed Web of Science ®Google Scholar
• Gamis AS, Alonzo TA, Meshinchi S, et al. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III children’s oncology group trial AAML0531. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2014 Sep 20;32(27):3021–3032.
   PubMed Web of Science ®Google Scholar
• Marcucci G, Geyer S, Zhao W, et al. Adding KIT inhibitor dasatinib (DAS) to chemotherapy overcomes the negative impact of KIT mutation/over-expression in core binding factor (CBF) acute myeloid leukemia (AML): results from CALGB 10801 (Alliance). Blood. 2014;124(21):8.
   Google Scholar